Inhibikase Therapeutics ($IKT) Insider Trading & Smart Money Activity
Inhibikase Therapeutics, Inc. ($IKT) has 2 insider trades and 2 analyst ratings on file. Insiders filed 2 Form 4 transactions in the last 12 months, none of them open-market purchases or sales.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 2
IKT insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All IKT insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | David Canner | Buy (Grant or award) | 155K sh | +3.7% | +23.0% | Read | |||||
| Insider | Vincent Aurentz | Buy (Grant or award) | 155K sh | +3.7% | +23.0% | Read | |||||
| Analyst | Oppenheimer | Reiterates to buy | PT $5 | +1.2% | +22.9% | Read | |||||
| Analyst | Oppenheimer | Reiterates to buy | PT $5 | +1.2% | +22.9% | — |
1W / 1M / 6M = how IKT moved from the trade or filing date.
Insider trading in IKT: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| David Canner | 1 | — | Jun 26, 2026 | ||
| Vincent Aurentz | 1 | — | Jun 26, 2026 |
Analyst ratings on IKT
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Oppenheimer | Reiterates | buy | $5 | +1.2% | +22.9% | Read | ||
| Oppenheimer | Reiterates | buy | $5 | +1.2% | +22.9% | — |
Frequently asked questions
What is the latest insider trade in IKT?
David Canner filed a buy (grant or award) of 155K sh on Jun 26, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.